Known targets — ChEMBL curated mechanism
CDK2CDK4CDK6CHEK1PDPK1PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3
The experimentally established mechanism targets of Ucn-01. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ known ✓ | Q04759 | 14/20 | 1.00 |
| ▸ | PRKCD known ✓ | Q05655 | 13/20 | 1.00 |
| ▸ | PRKD3 known ✓ | O94806 | 12/20 | 1.00 |
| ▸ | PRKCG known ✓ | P05129 | 12/20 | 1.00 |
| ▸ | PRKCZ known ✓ | Q05513 | 12/20 | 1.00 |
| ▸ | PRKCE known ✓ | Q02156 | 12/20 | 1.00 |
| ▸ | PRKCB known ✓ | P05771 | 11/20 | 1.00 |
| ▸ | PRKCA known ✓ | P17252 | 11/20 | 1.00 |
| ▸ | PRKCH known ✓ | P24723 | 11/20 | 1.00 |
| ▸ | PRKCI known ✓ | P41743 | 11/20 | 1.00 |
| ▸ | PRKD1 known ✓ | Q15139 | 11/20 | 1.00 |
| ▸ | CHEK1 known ✓ | O14757 | 5/20 | 1.00 |
| ▸ | CDK2 known ✓ | P24941 | 3/20 | 1.00 |
| ▸ | PDPK1 known ✓ | O15530 | 3/20 | 0.73 |
| ▸ | CDK4 known ✓ | P11802 | 2/20 | 0.73 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.73 |
| ▸ | PRKACA | P17612 | 9/20 | 1.00 |
| ▸ | PRKACG | P22612 | 8/20 | 1.00 |
| ▸ | PRKACB | P22694 | 8/20 | 1.00 |
| ▸ | EGFR | P00533 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ucn-01 SCHEMBL14217901 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL14190736 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL17470230 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13169435 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL259162 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL24105650 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13170168 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL20068300 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL13933132 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ | |
| Ucn-01 SCHEMBL1551632 | 1.00 | PRKCQ (1.00) | PRKCQPRKCDPRKD3PRKCGPRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2284 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| EP-4735448-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| EP-4688775-A1 | SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250387643-A1 | METHODS AND APPARATUS FOR APPLYING TUMOR TREATING FIELDS COMBINED WITH PERSONALIZED ULTRA-FRACTIONATED STEREOTACTIC ADAPTIVE RADIOTHERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-12-25 | — | — | US | claimed |
| US-12472259-B2 | PKC inhibitors for the treatment of septic cholestasis with polymethine dye targeting | SMARTDYELIVERY GMBH (DE) | 2025-11-18 | — | — | US | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| US-11382903-B2 | Cancer therapy | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2022-07-12 | — | — | US | claimed |
| US-20220211783-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | TRINITY CAPITAL INC., AS AGENT | 2022-07-07 | — | — | US | claimed |
| US-20220144805-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2022-05-12 | — | — | US | claimed |
| US-11311548-B2 | Cancer therapy | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2022-04-26 | — | — | US | claimed |
| WO-2022061251-A1 | COMPOUNDS AND METHODS FOR KRAS MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2022-03-24 | — | — | WO | claimed |
| US-20220061311-A1 | COMPOSITIONS AND METHODS FOR REDUCING CRYOPRESERVATION TOXICITY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-03-03 | — | — | US | claimed |
| EP-3955943-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | Candel Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |